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A straightforward chemoenzymatic synthesis of luliconazole has been 
developed. The key step involved the preparation of the 
enantiomerically pure β-halohydrin (1S)-2-chloro-1-(2,4-
dichlorophenyl)-1-ethanol through kinetic resolution of the 
corresponding racemic acetate, via hydrolytic approach, mediated by 
lipase from Thermomyces lanuginosus or Novozym 435®. This latter 
enzyme proved to be a robust biocatalyst in the kinetic resolution, 
leading to the (S)-β-halohydrin with high selectivity (e.e. > 99%, E > 
200) in just 15 min, at 45 °C, and being reused for five-times with 
maintenance high values of both conversion and enantioselectivity. 
Subsequently, the (S)-β-halohydrin was subjected to a mesylation 
reaction and the mesylated derivative reacted with 1-
cyanomethylimidazole leading to luliconazole in 43% yield and 
enantiomeric excess > 99%. 
Introduction 
Luliconazole (R-7), Scheme 1, also chemically known as (-)-
(2E)-[(4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene](1H-
imidazol-1-yl)acetonitrile, is a pharmaceutically active substance 
marketed under the brand names Luzu® (Valeant 
Pharmaceuticals North America) and Lulicon® (Pola Pharma), 
among others.[1,2]  This drug has antifungal action, being used for 
the treatment of tinea pedis, popularly known as athlete's foot, in 
addition to the treatment against of both candidiasis and 
pityriasis.[3] In vitro, (R)-7 is one of the most potent antifungal 
agents against filamentous fungi including dermatophytes.[4] 
Luliconazole was developed in Japan and approved by Japanese 
health agencies in 2005.[4] More recently, in 2013, the US FDA 
approved the (R)-7 for the treatment of tinea pedis interdigital, 
tinea cruris and tinea corporis caused by the microorganisms 
Trichophyton rubrum and Epidermophyton floccosum.[5]  It is 
noteworthy that the stereoisomers of luliconazole, (S,E) and/or Z-
isomers, are considered impurities and should be removed to 
obtain the enantiomerically pure active pharmaceutical ingredient 
(R)-7.[1]  The antifungal action exhibited by (R)-7 resides in the fact 
that this substance inhibits  the enzyme sterol 14α-demethylase 
(CYP51), which participates in the key step of ergosterol 
biosynthesis.[6] The mechanism of inhibiton includes the 
coordination of one of the nitrogen atoms of the imidazole ring 
with the iron atom of the heme group of the enzyme.[6]   
The syntheses of luliconazol have been reported envolving 
some chiral strategies, such as asymmetric induction in the 
presence of oxazaborolidines,[1,7] dihydroxylation of Sharpless[7] 
and chiral catalysts based on ruthenium, iridium or rhodium.[8]  
Herein, we report an unprecedented approach to obtain 
luliconazole, consisting of a lipase mediated chemoenzymatic 
synthesis, which has the preparation of a chiral β-halohydrin 
intermediate as key step. The importance of the preparation of 
chiral β-halohydrins lies in the fact that they are intermediates in 
the synthesis of substances with high added value.[9,10]  
One of the methods used to obtain chiral β-halohydrins is the 
enzymatic kinetic resolution of the corresponding racemate 
mediated by lipases.[11] There are some reports of the kinetic 
resolution of β-halohydrins containing aromatic ring moiety via the 
acylation reaction, as well as from their corresponding esters, via 
hydrolytic process. Several lipases have been used in both 
processes such as Pseudomonas fluorescens,[12,13,14] 
Burkholderia cepacia,[15,16,17] Candida antarctica type B (Novozym 
435®),[13,18,19] P. cepacia, [20,21,22,23,24] C. rugosa,[21] Pseudomonas 
sp.[25] and P. aeruginosa.[26] In some of these examples, the 
kinetic resolution was performed in the presence of ionic 
liquids[17,23] or by dynamic kinetic resolution in the presence of 
ruthenium as racemization agent.[20,26] 
Lipases (EC 3.1.1.3) are highlighted as one of the most used 
enzymes in synthesis of enantiomerically pure drugs since no 
cofactors are required and regio-, chemo- and enantioselectivities 
are observed in the resolution process of racemates. Since most 
of the drugs are chiral, it is important to know which of the 
stereoisomers has the desired biological activity. Thus, the patient 
receives only one dose of the active stereoisomer, avoiding the 
side effects caused by the undesired stereoisomer. Therefore, 
biocatalysis represents an alternative tool for the production of 
enantiomerically pure chiral drugs over conventional chemical 
processes.[27] 
In this paper, we describe the chemoenzymatic synthesis of 
luliconazole (R)-7, which had as key step the preparation of the 
chiral β-halohydrin (1S)-2-chloro-1-(2,4-dichlorophenyl)-1-
ethanol (S)-2, via kinetic resolution of acetate rac-3, mediated by 
a lipase, Scheme 1. Our focus was to perform an optimization of 
the reactional conditions, including the enzymes recycling 
outcome.  
Results and Discussion 
The chemoenzymatic synthesis of luliconazole is depicted in 
Scheme 1. The key step was the kinetic enzymatic resolution of 
the racemic 2-chloro-1-(2,4-dichlorophenyl)ethyl acetate (rac-3), 
via a hydrolytic approach, mediated by a lipase. 
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Scheme 1. Chemoenzymatic synthesis of luliconazole. 
Synthesis of racemic halohydrin (rac-2) and its acetate (rac-
3) 
 As first step, the chemical reduction of the α-chloroketone 1 
was carried out by using sodium borohydride (0.5 eq.) in MeOH[28] 
to yield rac-2 in 90% yield. Next, the chemical acetylation of rac-
2 was performed using Ac2O, DMAP and Et3N at room 
temperature for 2 h[29] and allowed the preparation of rac-3 with 
91% isolated yield, Scheme 1. Adequate chiral GC analyses were 
developed for both rac-2 and rac-3 in order to achieve a reliable 
method to measure the enantiomeric excesses of both remaining 
substrate and the final product from the lipase-catalyzed 
resolution, Fig. 1. 
 
Figure 1. A) GC chromatogram of rac-2-chloro-1-(2,4-dichlorophenyl)ethyl 
acetate (rac-3: (R) tR 8.33 min; (S) tR 8.82 min). B) GC chromatogram of rac-2-
chloro-1-(2,4-dichlorophenyl)1-ethanol (rac-2: (S) tR 17.90 min.; (R) tR 18.50 
min). 
Screening of lipase-mediated kinetic resolution of acetate 
rac-3 via hydrolysis  
 For initial screening of lipases, twelve commercially 
available enzymes (ratio 2:1 in weight respect to rac-3) were tried 
in the resolution of rac-3 at 30 °C, 250 r.p.m., phosphate buffer 
pH 7 (0.1M). Reactions were monitored for a maximum of 24 h 
and stopped before this time if the conversion had reached a 
value close to 50%. The product β-halohydrin (S)-2 and the 
remaining acetate (R)-3 were obtained, and the results are 
summarized in Table 1.  
 
   
Table 1. Kinetic resolution of rac-3, via hydrolysis using lipases.a 









1 P. fluorescens 19 77 70 52 13 
2 P. camemberti 24 3 3 50 1 
3 R. miehei 
immobilized on 
anionic resin 
14 60 57 51 6 
4 Amano lipase 





19 73 66 52 10 
5 Amano lipase 
PS from B. 
cepacia 
19 80 74 52 16 
6 TLLe 24 >99 92 52 128 
7 Novozym 435® 24 97 95 50 185 
8 Amano lipase 
from M. 
javanicus 
24 11 59 16 4 
9 C. rugosa 24 9 48 16 3 
10 Porcine 
pancreas 
24 3 3 50 1 
11 R. niveus 24 1 64 2 5 
12 R. oryzae 
immobilized on 
immobead-150 
19 53 57 48 6 
[a] Conditions: 30 °C, lipase:rac-3 (2:1) at 250 r.p.m. [b] 
Determined by GC. [c] Conversion, c = e.e.s/(e.e.s + e.e.p). 
[d] Enantiomeric ratio, E = ln[1 − c(1 + e.e.p)]/ln[1 − c(1 − 
e.e.p)]. [e] TLL:  T. lanuginosus immobilized on immobead-
150. 
  
   
Among the lipases evaluated in the hydrolysis reaction of rac-
3, Thermomyces lanuginosus immobilized on immobead-150 
(TLL) and CAL-B (Novozym 435®) were the enzymes that 
provided better results. Conversions of 52 and 50%, and E values 
of 128 and 185 were observed, respectively, in 24 h of reaction 






(Table 1, entries 6 and 7). On the other hand, lipase from 
Rhizomucor miehei immobilized on anionic resin was the enzyme 
with the highest activity in the kinetic resolution of rac-3, with a 
conversion of 51% in only 14 h, but with low selectivity (E value 
of 6), Table 1 entry 3. Lipase from Rhizopus niveus was the less 
active enzyme, leading to a conversion of only 2% in 24 h of 
reaction, (Table 1, entry 11).  
The remainder of the lipases evaluated, as P. fluorescens, 
Penicillium camemberti, Amano PS from B. cepacia immobilized 
on diatomaceous earth, Amano PS from B. cepacia, Amano 
lipase from Mucor javanicus, C. rugosa, porcine pancreas and 
Rhizopus oryzae immobilized on immobead-150, led to 
conversions of about 50%, but with low enantioselectivity (E 
values ranging from 1 to 16; Table 1 entries 1, 2, 4, 5, 8, 9, 10 and 
12, respectively).  
Improving the kinetic resolution of rac-3 through 
temperature variation 
In order to improve enzymatic resolution of rac-3, we 
performed a detailed study of the reaction condition, varying some 
parameters, such as temperature, reaction time and the ratio 
enzyme/substrate (w/w). For this study, we selected the enzymes 
TLL immobilized on immobead-150 and Novozym 435® that were 
most promising in the kinetic resolution of rac-3 (Table 1, entries 
6 and 7). In addition, since these two lipases are commercially 
immobilized, reuse studies have been performed. 
In order to reduce the reaction time, the first variable to be 
changed was the temperature. With additions of 5 °C, the kinetic 
resolution of rac-3 was evaluated at 35, 40 and 45 °C. The results 
were summarized in Table 2. 
 
 
As we increased the temperature by 5 °C (from 30 to 35 °C), 
there was a decrease in reaction time from 24 to 16 h for both 
Novozym 435® and TLL enzymes, Table 2, entries 1 and 6. 
However, with Novozym 435® we observed an increase in the 
enantiomeric excess values for both product and remaining 
substrate (> 99%), Table 2, entry 1. No significant changes in the 
enantiomeric excess values of product and remaining substrate 
were observed for TLL, Table 2, entry 6. On the other hand, the 
increment of 5 °C in the temperature (from 35 to 40 °C) led to a 
significant decrease in reaction time from 16 to 2 h (Table 2, 
entries 2 and 7). In this case, both lipases yielded the product and 
the remaining substrate with enantiomeric excess > 99%. A 
surprising result was obtained when the kinetic resolution was 
performed at 45 °C. At this temperature, the reaction time for an 
ideal kinetic resolution was only 15 min and both lipases led to the 
product and remaining substrate with enantiomeric excess > 99%, 
conversion of 50% and E value > 200 (Table 2, entries 4 and 8). 
Once the ideal temperature (45 °C) was determined, at 
which the kinetic resolution of rac-3 occurred in the shortest 
possible time (15 min), we decided to evaluate the decrease of 
the loaded enzyme on the reaction. 
 
Effect of enzyme load in the kinetic resolution of rac-3 
 
For Novozym 435®, the ratio enzyme:substrate was 
gradually decreased (from 2:1 to 0.25:1) and the kinetic resolution 
of rac-3 remained efficient up to 0.5:1 (w:w). Enantiomeric excess 
> 99%, 50% conversion and E value > 200 was observed for both 
product and substrate, Table 2, entry 4. However, with an 
enzyme:substrate ratio of 0.25:1, the conversion had a slight 
decrease (43%) leading to an enantiomeric excess of substrate 
remaining of 76%, Table 2, entry 5. For TLL to maintain an optimal 
kinetic resolution of rac-3, the lowest enzyme:substrate ratio was 
1.5:1, Table 2, entry 9. When we decreased the ratio to 1:1, the 
conversion showed a decrease (30%) and the enantiomeric 
excess of the substrate was only 41%, Table 2, entry 10. 
Finally, since the most efficient enzymes (Novozym 435® 
and TLL) in the kinetic resolution of rac-3 are commercially 
immobilized, we decided to carry out a study of their reuse in ten 
reaction cycles. 
 
Reuse of the immobilized lipases 
 
 This study was carried out in order to investigate the 
efficiency of Novozym 435® and TLL in maintaining satisfactory 
conversion and enantioselectivity values up to ten cycles of reuse 
(Fig. 2 and 3). 
 
aConditions: phosphate buffer pH 7 (0.1M), 45 ºC, lipase:rac-3a (0.5:1) and 15 
min at 250 rpm. 
 
Figure 2. Results from the reuse of Novozym 435®.a 
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Table 2. Results of kinetic resolution of rac-3, via hydrolysis, mediated by 
lipases, varying temperature and enzyme/substrate ratio (w/w). 











35 960 >99 >99 50 >200 
2d Novozym 
435® 
40 120 >99 >99 50 >200 
3d Novozym 
435® 
45 15 >99 >99 50 >200 
4e Novozym 
435® 
45 15 >99 >99 50 >200 
5f Novozym 
435® 
45 15 76 >99 43 >200 
6d TLLg 35 960 97 96 50 >200 
7d TLLg 40 120 >99 >99 50 >200 
8d TLLg 45 15 >99 >99 50 >200 
9h TLLg 45 15 >99 >99 50 >200 
10i TLLg 45 15 41 >99 30 >200 
[a] Determined by GC. [b] Conversion, c = e.e.s/(e.e.s + e.e.p). [c] 
Enantiomeric ratio, E = ln[1 − c(1 + e.e.p)]/ln[1 − c(1 − e.e.p)]. [d] 
lipase:rac-3 (2:1). [e] lipase:rac-3 (0.5:1). [f] lipase:rac-3 (0.25:1). [g] 
TLL:  T. lanuginosus immobilized on immobead-150. [h] lipase:rac-3 
(1.5:1). [i] lipase:rac-3 (1:1). 







aConditions: phosphate buffer pH 7 (0.1M), 45 ºC, lipase:rac-3a (1.5:1) and 15 
min at 250 rpm. 
Figure 3. Results from the reuse of TLL immobilized on immobead-150.a  
Conversion values close to 50% were observed for Novozym 
435® during ten reused cycles. Additionally, it was obtained 
enantiomeric excess values of product greater than 90% up to the 
fifth reaction cycle.  From the sixth reaction cycle, the enzyme lost 
some of its selectivity, with enantiomeric excess values of product 
varying between 81 and 89% (Fig. 2). 
When the reuse study was performed with TLL, it was verified 
that in the second reaction cycle the activity decreased to 37%, a 
value that remained constant until the fifth reaction cycle. In the 
next reaction cycles, there was a slight decrease in the conversion 
values, culminating in a conversion of 30% in the last cycle. 
Concerning the selectivity, it was observed that the enantiomeric 
excess of the product decreased to 90% in the second reaction 
cycle and continued progressively decreasing until the tenth cycle 
at a value of 65% (Fig. 3). 
Once the enzymatic loading and reuse studies were 
performed, it was possible to verify that Novozym 435® presented 
more advantages compared to TLL. In fact, Novozym 435® 
required a lower enzyme:substrate ratio (0.5:1) in detriment of 
1.5:1 to TLL. Moreover, Novozym 435® can be reused in up to five 
reaction cycles maintaining high values of selectivity and 
conversion. On the other hand, in the presence of TLL, the 
conversion showed a considerable decrease already in the 
second reaction cycle, followed by a progressive decrease in the 
selectivity in the subsequent reaction cycles. 
After optimizing the enzymatic kinetic resolution of rac-3, we 
proceed with the following steps to obtain luliconazole (R)-7. 
Synthesis of luliconazole (R)-7 
 The kinetic resolution of rac-3 was performed under the 
optimized conditions (Scheme 1), phosphate buffer (pH 7), 
Novozym 435®, enzyme:substrate (0.5:1), 45 °C and 15 min of 
reaction, and provided the β-halohydrin (S)-2 and the remaining 
acetate (R)-3 with enantiomeric excess values > 99%, conversion 
of 50% and enantioselectivity (E) > 200. 
 Posteriorly, the (S)-2 was subjected to a mesylation reaction 
with MsCl, DMAP, Et3N in CH2Cl2 for 7 h to give the mesylated 
product (S)-4 in 89% yield and enantiomeric excess >99%, 
Scheme 1.[30]  
Concomitantly, 1-cyanomethylimidazole 6 was obtained in 
70% yield from the reaction of imidazole 5 with bromoacetonitrile, 
NaH in dry THF for 4 h, Scheme 1.[31] 
Finally, in the last step, the mesylate (S)-4 was subjected to 
the reaction with 1-cyanomethylimidazole 6 in the presence of 
CS2, K2CO3 in DMF, at room temperature and 24 h of reaction.[32] 
However, under such conditions the substrate (S)-4 was 
recovered unchanged from the reaction medium. In search of 
better reaction conditions, we decided to use KOH as base and 
DMSO as the solvent. In this case, we obtained a mixture of the 
E (R-7) and Z (R-8) isomers in a ratio of 2:1. After purification, the 
luliconazole (E-isomer) was obtained in 43% yield and 
enantiomeric excess > 99%, Scheme 1.[6]  
Conclusions 
In summary, we prepared luliconazole via an original 
approach involving the chemoenzymatic process using lipases. 
Both lipases TLL immobilized on immobead-150 and Novozym 
435® were able to resolve the racemic 2-chloro-1-(2,4-
dichlorophenyl)ethyl acetate (rac-3) via a hydrolytic process. The 
enantiomerically pure key intermediate β-halohydrin (1S)-2-
chloro-1-(2,4-dichlorophenyl)-1-ethanol (S)-2 was obtained with 
conversion of 50% in only 15 min of reaction. Novozym 435® 
stood out as the best lipase because it required a lower enzymatic 
load enzyme:substrate (0.5:1) compared to TLL (1.5:1). Moreover, 
Novozym 435® proved to be a robust biocatalyst, since it could be 
reused in five reaction cycles, maintaining high values of both 
conversion and enantioselectivity. Finally, this unprecedented 
approach to obtain luliconazole can be considered eco-friendly, 
since a stable, low cost, reusable, commercially available and 
highly enantioselective biocatalyst was used. 
Experimental Section 
Enzymes 
(i) Immobilized lipases: C. antarctica lipase type B 
immobilized on acrylic resin (CAL-B, Novozym 435, 7,300.0 U/g) 
and R. miehei lipase immobilized on anionic resin (RML, 150.0 
U/g) were purchased from Novozymes®. B. cepacia lipase 
immobilized on diatomaceous earth (Amano PS-IM, ≥500 U/g), T. 
lanuginosus lipase immobilized on immobead-150 (TLL, 250.0 
U/g) and R. oryzae lipase immobilized on immobead-150 (ROL, 
340.0 U/g) were acquired from Sigma-Aldrich®. (ii) Crude lipase 
preparations: M. javanicus lipase (Amano M, ≥10,000 U/g), R. 
niveus lipase (RNL, 1,5 U/mg), B. cepacia lipase (Amano PS, 
≥30,000 U/g), P. fluorescens lipase (AK, 22,100.0 U/g), P. 
camemberti lipase (Amano G, 50.0 U/g) were acquired from 
Sigma-Aldrich®. Porcine pancreas lipase (PPL, 46.0 U/g solid), 
and C. rugosa lipase (CRL, 1.4 U/g) were obtained from Sigma-
Aldrich®.  
Chemical Materials 
Chemical reagents were purchased from different commercial 
sources and used without further purification. Methanol, DMF, 
chloroform, DMSO, ethyl acetate and dichloromethane were 
acquired from Synth®. Tetrahydrofuran and carbon disulfide were 
acquired from Sigma-Aldrich®. Solvents were distilled over an 
adequate desiccant under nitrogen. Analytical TLC analyses were 
performed on aluminum sheets pre-coated with silica gel 60 F254 
(0.2 mm thick) from Merck®. Flash chromatographies were 
performed using silica gel 60 (230-240 mesh). 
99 90 87 88 83 73 72 70 68 65
50















Melting points were determined in open capillary tube 
Microquímica model MQAPF-302 and are uncorrected. 1H and 
13C NMR were obtained using Spectrometer Bruker model 
Avance DPX 300, operating at frequency of 300 MHz for 
hydrogen and frequency of 75 MHz for carbon. The chemical 
shifts are given in delta (δ) values and the coupling constants (J) 
in Hertz (Hz). Measurement of the optical rotation was done in a 
Jasco P-2000 polarimeter. Gas chromatograph (GC) analyses 
were carried out in a Shimadzu chromatograph model GC 2010 
with a flame ionization detector using a chiral column CP-chirasil-
dex (25 m x 0.25 mm x 0.25 µm, 0.5 bar N2). For the following of 
the reaction time courses: rac-2-chloro-1-(2,4-
dichlorophenyl)ethyl acetate (rac-3): 185 ºC; 1 ºC/min. 190 ºC 
(hold 5 min.); 0.5 ºC/min. 200 ºC (hold 15 min.). Retention times 
were: (R)-acetate= 8.33 min.; (S)-acetate= 8.82 min. Haloydrin 
rac-2 was analyzed using a chiral column Rt®bDEXcst (30 m x 
0.39 mm x 0.25 µm, 0.5 bar N2). For the following of the reaction 
time courses: rac-2-chloro-1-(2,4-dichlorophenyl)ethanol (rac-2): 
185 ºC; 1 ºC/min. 190 ºC (hold 5 min.); 0.5 ºC/min. 200 ºC (hold 
15 min.). Retention times were: (S)-halohydrin= 17.90 min.; (R)-
halohydrin= 18.50 min. 
Synthesis of rac-β-halohydrin (rac-2)  
 A mass of 2-chloro-1-(2,4-dichlorophenyl)ethanone (1) (1 g, 
4.5 mmol) was dissolved in MeOH (40 mL). Then, NaBH4 (0.085 
g, 2.2 mmol) of was added slowly at 0 °C. The reaction was stirred 
for 30 min at room temperature. Upon completion, the MeOH was 
evaporated under reduced pressure. Then, 1 M HCl (10 mL) of 
was added followed by extraction with EtOAc (4 x 60 mL). Organic 
phases were combined and dried over anhydrous Na2SO4, filtered 
and solvent was evaporated under reduced pressure. Then, the 
crude product was purified by performing column 
chromatography, employing silica gel and CHCl3 to afford rac-β-
halohydrin rac-2 in 90% yield (0.913 g, 4.0 mmol). 
Synthesis of rac-acetate (rac-3)  
 A suspension of DMAP (0.054 g, 0.4 mmol) and acetic 
anhydride (1.25 mL, 13.3 mmol) was dissolved in CH2Cl2 (40 mL). 
Then, rac-2 (1 g, 4.4 mmol) and triethylamine (616.3 µL, 4.4 
mmol) were added. The reaction was stirred for 2 h at room 
temperature. After this time, distilled water (10 mL) was added 
followed by extraction with CH2Cl2 (3 x 50 mL). The organic 
phases were combined and dried over anhydrous Na2SO4. Then, 
after filtration, the solvent was evaporated under reduced 
pressure and the crude product was purified using a silica gel 
column chromatography and CHCl3 to afford rac-acetate rac-3 in 
91% yield (1.071 g, 4.0 mmol). 
Synthesis of (1S)-2-chloro-1-(2,4-dichlorophenyl)-2-
methanesulfonate (S-4) 
 A mass of (S)-2 (0.5 g, 2.2 mmol) of was dissolved in CH2Cl2 
(25 mL) at 0 °C. Then, triethylamine (307 µL, 2.2 mmol), DMAP 
(0.027 g, 0.2 mmol) and MsCl (855 µL, 11.0 mmol) were added in 
0 ºC for 1 h. Then, the reaction mixture was stirred at room 
temperature for 6 h. After this time, 20 mL of distilled water was 
added followed by extraction with CH2Cl2 (3 x 40 mL). Then, the 
organic phase were combined and treated with saturated 
aqueous NaHCO3 solution (20 mL) and the organic phase was 
collected and dried with anhydrous Na2SO4. Finally, after filtration, 
the solvent was evaporated under reduced pressure and the 
crude product was purified using column chromatography with 
silica gel (CHCl3/hexane 7:3) to afford (S)-4 as yellow solid in 89% 
yield (0.607 g, 2.0 mmol). 
Synthesis of 1-cyanomethylimidazole (6) 
 To a solution of imidazole (5) (0.5 g, 7.3 mmol) in dry THF 
(50 mL) under nitrogen atmosphere, NaH (0.176 g, 7.3 mmol) was 
added until complete release of hydrogen. After, 
bromoacetonitrile (510 µL, 7.3 mmol) was added dropwise, with 
the appearance of a yellow color in the reaction. The reaction 
mixture was stirred for 4 h at room temperature. Then, the solvent 
was evaporated under reduced pressure and distilled water (10 
mL) was added followed by extraction with CH2Cl2 (3 x 50 mL). 
The organic phase was dried over anhydrous Na2SO4. After 
filtration, the solvent was evaporated under reduced pressure. 
Then, the crude product was purified by performing column 
chromatography on silica gel (CHCl3/MeOH 9.5:0.5) to afford (6) 
as a brown solid in 70% yield (0.546 g, 5.1 mmol). 
Synthesis of luliconazole (R-7) 
 A mass of KOH (0.210 mg, 3.7 mmol) was dissolved in 
DMSO (3 mL). Then, 6 (0.1 g, 0.9 mmol) and carbon disulfide (56 
µL, 0.9 mmol) in of DMSO (3 mL) at 4 ºC were added. The 
reaction was stirred for 2 h at room temperature to form the 
dithiolate salt. Then, (S)-4 (0.560 g, 1.9 mmol) was added slowly 
at 4 °C and the reaction was stirred for 24 h at room temperature. 
After this time, cold water (30 mL) was added and the reaction 
mixture was stirred for 10 min. Then, the product was extracted 
with EtOAc (3 x 40 mL) and the organic phase were washed with 
ice water (2 x 20 mL), dried over anhydrous Na2SO4, filtered and 
concentrated under reduced pressure. The crude product was 
purified using column chromatography with silica gel 
(CHCl3/CH3CN 9:1) to afford the (R,Z)-isomer with 19% yield 
(0.062 g, 0.18 mmol) and (R)-7 as yellow solid in 43% yield (0.141 
g, 0.4 mmol). 
General procedure for the lipase-catalyzed hydrolysis of rac-
3  
A suspension of rac-3 (0.030 g, 0.1 mmol) and lipase (ratio 
2:1 in weight respect to the rac-3) in phosphate buffer 100 mM 
pH 7.0 (1.0 mL) was shaken in their proper temperature and time 
reaction at 250 rpm. After the conversion reaches a value close 
to 50%, the products were extracted with EtOAc (3 x 5 mL). The 
organic phases were combined and dried over Na2SO4, filtered 
and the solvent evaporated under reduced pressure. The reaction 
crude was purified by flash chromatography on silica gel (100% 
CHCl3), yielding (R)-acetate (R-3) and (S)-halohydrin (S-2) being 
their enantiomeric excess determined by GC. 
Synthesis of (R)-3 and (S)-2 mediated by Novozym 435® 
A suspension of rac-3 (0.5 g, 1.9 mmol) and 0.25 g of 
Novozym 435® in phosphate buffer 100 mM pH 7.0 (19 mL) was 
shaken in 45 ºC and 15 min at 250 rpm. After the conversion has 
reached a value close to or 50%, the products were extracted with 
EtOAc (3 x 20 mL). The organic phases were combined and dried 
over Na2SO4, filtered and the solvent evaporated under reduced 
pressure. The reaction crude was purified by flash 
chromatography on silica gel and CHCl3, yielding 46.5% of (R)-
acetate (R-3) (0.454 g, 1.7 mmol) with [α]D23=-52.3 (c=1.0 in ethyl 
acetate) for 99% e.e. and 44.5% of (S)-halohydrin (S-2) (0.383 g, 
1.7 mmol) with [α]D20=+51.1 (c=2.50 in chloroform) for 99% e.e.; 
Lit [α]D25=-52.8 (c=2.55 in chloroform) for 99% e.e. of the (R)-
enantiomer.[33]  






 rac-2-chloro-1-(2,4-dichlorophenyl)ethanol (rac-2): 90% 
yield. Orange solid.  Rf=0.45 (CHCl3); m.p. 47-49 C; Lit m.p. 46-
47 C;[15] 1H NMR (300 MHz, CDCl3, TMS): δ=2.50 (br s, OH, 1H), 
3.52 (dd, J=11.8, 5.0 Hz, 1H), 3.87 (dd, J=8.3, 2.0 Hz, 1H), 5.26 
(dd, J=6.0, 2.7 Hz, 1H), 7.31 (dd, J=10.1, 2.3 Hz, 1H), 7.38 (d, 
J=1.8 Hz, 1H), 7.57 ppm (d, J=8.0 Hz, 1H); 13C NMR (75 MHz, 
CDCl3, TMS): δ=49.4 (CH2), 70.5 (CH), 127.8 (CH), 128.7 (CH), 
129.5 (CH), 132.7 (C), 134.8 (C), 136.1 ppm (C). 
rac-2-chloro-1-(2,4-dichlorophenyl)ethyl acetate (rac-3): 
91% yield. Yellow liquid. Rf=0.61 (CHCl3); 1H NMR (300 MHz, 
CDCl3, TMS): δ=2.17 (s, 3H), 3.72 (dd, J=11.8, 4.9 Hz, 1H), 3.84 
(dd, J=11.8, 8.1 Hz, 1H), 6.31 (dd, J=10.6, 3.7 Hz, 1H), 7.28 (dd, 
J=10.5, 2.1 Hz, 1H), 7.37 (d, J=8.4 Hz, 1H), 7.40 ppm (d, J=1.9 
Hz, 1H); 13C NMR (75 MHz, CDCl3, TMS): δ=21.0 (CH3), 45.2 
(CH2), 71.4 (CH), 127.7 (CH), 128.9 (CH), 129.8 (CH), 133.2 (C), 
133.7 (C), 1353 (C), 169.6 ppm (C). 
(S)-2-chloro-1-(2,4-dichlorophenyl)-2-methanesulfonate (S-
4): 89% yield. Yellow solid. Rf=0.45 (CHCl3/hexane 7:3); m.p. 73-
76 C; [α]D20=+64.0 (c=1.0 in chloroform) for 99% e.e.; 1H NMR 
(300 MHz, CDCl3 TMS): δ=3.09 (s, 3H), 3.75 (dd, J=12.1, 4.7 Hz, 
1H), 3.84-3.87 (m, 1H); 6.05 (dd, J=9.3, 3.5 Hz, 1H), 7.27-7.32 
(m, 1H), 7.34-7.38 (m, 1H), 7.51-7.59 ppm (m, 1H); 13C NMR (75 
MHz, CDCl3, TMS): δ=38.9 (CH3), 45.3 (CH2), 78.7 (CH), 128.1 
(CH), 129.1 (CH), 129.9 (CH), 132.4 (C), 132.7 (C), 136.2 ppm 
(C). 
1-cyanomethylimidazole (6): 70% yield. Brown solid. 
Rf=0.50 (CHCl3/MeOH 9.5:0.5); m.p. 141-142 C; Lit m.p. 138 C;[34] 
1H NMR (300 MHz, CDCl3, TMS): δ=4.92 (s, 1H), 7.10 (s, 1H), 
7.27 (s, 1H), 7.55 ppm (s, 1H); 13C NMR (75 MHz, CDCl3, TMS): 
δ=34.5 (CH2), 113.8 (C), 119.1 (CH), 130.9 (CH), 137.2 ppm 
(CH). 
(R,Z)-Isomer (R-8): 19% yield. Yellow solid. Rf=0.41 
(CHCl3/CH3CN 9:1); m.p. 113-115 C; 1H NMR (300 MHz, CDCl3, 
TMS): δ=3.74 (dd, J=18.0, 6.0 Hz, 1H), 3.96 (dd, J=15.0, 3.0 Hz, 
1H), 5.63 (dd, J=15.0, 6.0 Hz, 1H), 7.06 (s, 1H), 7.17 (s, 1H), 7.27-
7.33 (m, 1H), 7.46 (d, J=1.0 Hz, 1H), 7.52 (d, J=9.0 Hz, 1H), 7.65 
ppm (s, 1H); 13C NMR (75 MHz, CDCl3, TMS) δ=44.2 (CH2), 55.6 
(CH), 77.6 (C), 114.6 (C), 119.3 (CH), 128.1 (CH), 129.2 (2CH), 
130.4 (2CH), 131.4 (C), 134.4 (C), 136.1 (C), 137.2 ppm (CH). 
 
Luliconazole (R-7): 43% yield. Yellow solid. Rf=0.45 
(CHCl3/CH3CN 9:1); m.p. 151-152 C; Lit m.p. 151.1 C;[35] [α]D20=-
50.7 (c=1.0 in dimethylformamide) for 99% e.e.; 1H NMR (300 
MHz, CDCl3, TMS): δ=3.66 (dd, J=11.6, 4.4 Hz, 1H), 3.89 (dd, 
J=10.3, 3.1 Hz, 1H), 5.70 (dd, J=7.6, 3.2 Hz, 1H), 7.06 (s, 1H), 
7.19 (s, 1H), 7.35 (dd, J=6.1, 1.1 Hz, 1H), 7.49 (d, J=1.1 Hz, 1H), 
7.59 (d, J=5.0 Hz, 1H), 7.66 ppm (s, 1H); 13C NMR (75 MHz, 
CDCl3, TMS) δ=42.8 (CH2), 44.4 (CH), 77.4 (C), 114.7 (C), 119.4 
(CH), 128.2 (CH), 129.2 (CH), 130.3 (2CH), 130.4 (C), 131.5 (C), 
134.4 (CH), 136.1 (C), 137.2 ppm (C).  
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A new approach based on biocatalysis was developed for the production of the potent 
antifungal luliconazole. The lipase Novozym 435® proved to be a robust biocatalyst 
in the key step involving the preparation of an enantiomerically pure β-halohydrin in 
only 15 min of reaction. The enzyme was reused in up to 5 reaction cycles with 
maintenance of high values of activity and selectivity. After a few more steps, 
luliconazole was obtained in good yield and enantiomeric excess. 
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